Recruiting
Glomerulonephritis rapidly progressive
RecruitingStudy on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis
Registered drug
Study on the Safety and Tolerability of Lixudebart and Rituximab for Patients with Rapidly Progressive Glomerulonephritis Due to ANCA-Associated Vasculitis
Registered drug
- Disease:Glomerulonephritis rapidly progressive
- Substances:LixudebartRituximab
Countries:
Czechia
Czechia- Participants:18–64 years · 65+ years
- Substances:Lixudebart



